Dietary Supplement Sales Projected to Double Over Next 3 Years; COVID-19 Stay-At-Home Orders Drive New Loyal Consumers

BOCA RATON, FL / ACCESSWIRE / July 14, 2020 / StemSation International, Inc. (OTC PINK:STSN) – a pioneer in the emerging category of dietary supplements called Stem Cell Nutrition, announces strong industry trends should favorably impact its growth.

According to the Nutrition Business Journal, online dietary supplement sales are projected to grow from $5 billion in 2019 to over $10 billion in 2022. Sales in 2020 are projected to grow 61.4% as stay-at-home orders drive more people to e-commerce and many are then expected to remain loyal to this channel.

Ray Carter, StemSation’s President and CEO commented, “it appears that current dynamics related to the pandemic are accelerating the positive trends towards dietary supplement purchasing. Our unique products are positioned to capture consumer attention and the efficacy of our formulations will keep them coming back for more”.

StemSation’s all-natural products focus on supporting the two most recently discovered biological systems of the human body, the stem cell system of renewal and repair, and the endocannabinoid system of regulating physiological functions in both the central and peripheral nervous system and in peripheral organs.

StemSation markets and sells its products online through its growing team of Independent Wellness Advocates in the United States and Europe, who each receive a StemSation replicated website in four languages and currencies.

StemSation is a company with a long-term ‘health mission’, ambitious research goals, and innovative, holistic approaches to health & wellness, and healthy longevity. Our product line shows a new pathway to wellness.


StemSation International, Inc. (OTC PINK:STSN) develops, manufactures and distributes natural wellness products that support the stem cell and endocannabinoid systems in the human body through using a direct selling model in which Independent Wellness Advocates (“IWAs”) advertise and sell its products directly to consumers. StemSation is headquartered in Boca Raton, Florida and its website can be located at


This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


Nicholas B. Panza, Vice-President
StemSation International, Inc.
7777 Glades Road
Suite 203
Boca Raton, FL 33434
(561) 245-7454

SOURCE: StemSation International, Inc.

View source version on

error: Content is protected !!